India's homegrown stroke device passes big test
AIIMS, Delhi just wrapped up the GRASSROOT trial for Supernova, an Indian-made stent retriever designed to treat major strokes.
The study ran from August 2024 to June 2025 with 32 patients, with an average age of 58 years.
Results landed in December 2025 in a top neurosurgery journal.
Supernova works—and works fast
Supernova restored blood flow in 94% of cases, usually after just one or two tries.
Three months later, half the patients could manage daily life on their own again.
There were no device-related complications; serious side effects were rare.
Why this matters for India
India's health regulator has now approved Supernova for routine use—the first time a locally made stroke device got the green light based entirely on Indian trials.
This means more affordable treatment options and less reliance on imports, which is huge since India faces about 1.7 million strokes every year.